Cellect Biotechnology (NASDAQ:APOP) soars 49% premarket after announcing that shareholders voted to approve the previous merger with privately-held Quoin Pharmaceuticals, a specialty company focused on rare and orphan diseases, and all other proposals at the special meeting, including the sale of the subsidiary to EnCellX, a privately held company based in San Diego, CA.
Tel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (APOP), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company’s clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company’s cell selection technology designed to optimize immune therapy, in this application - prevent graft-versus-host disease (GVHD) following bone marrow transplantation.